Abstract
The United States Food and Drug Administration has recently approved several new insulin
products and new formulations of existing insulin products. These new products may
provide advantages over older products, such as a lower risk of nocturnal hypoglycemia
and ease of dosing; however, they are costly. The first of 2 articles in a series,
this review will describe the potential advantages and disadvantages of these new
insulin products.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Standards of medical care in diabetes-2017.Diabetes Care. 2017; 40: S64-S74
- U.S. Food and Drug Administration Approves Humalog® 200 units/mL Kwikpen®.(Available at)https://investor.lilly.com/releasedetail.cfm?releaseid=914999Date accessed: November 20, 2017
- A primer on concentrated insulins: what an internist should know.Postgrad Med. 2016; 128: 381-390
- FDA approves Basaglar, a long-acting insulin treatment.(Available at)https://investor.lilly.com/releaseDetail.cfm?ReleaseID=947336Date accessed: March 9, 2018
- Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insuin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).Diabetes Obes Metab. 2015; 17: 734-741
- Sanofi receives approval of once daily basal insulin Toujeo.(Available at)http://www.news.sanofi.us/2015-02-25-Sanofi-Receives-FDA-Approval-of-Once-Daily-Basal-Insulin-ToujeoDate accessed: November 14, 2017
- A review of the safety and efficacy data for insulin glargine 300 units/mL, a new formulation of insulin glargine.Diabetes Obes Metab. 2015; 17: 1107-1114
- New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized, controlled trial (EDITION 1).Diabetes Care. 2014; 37: 2755-2762
- New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized, controlled trial (EDITION 2).Diabetes Care. 2014; 37: 3235-3243
- U.S. Food and Drug Administration Approves Humulin® U-500 Kwikpen.(Available at)https://investor.lilly.com/releasedetail.cfm?releaseid=951175Date accessed: November 14, 2017
- Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to-target clinical trial.Endocr Pract. 2015; 21 (Erratum, 2016;22(7):905): 782-793
- Tresiba approval history.(Available at)https://www.drugs.com/history/tresiba.htmlDate accessed: March 9, 2018
- Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized BEGIN trials.Endocr Pract. 2014; 20: 285-292
- The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes (BEGIN FLEX Trial).Diabetes Care. 2013; 36: 858-864
- Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.Ther Adv Chronic Dis. 2015; 6: 375-388
Article info
Publication history
Published online: February 26, 2018
Rhonda M. Cooper-Rettoff, PharmD, MS, Pharmacology Series EditorFootnotes
Funding: None.
Conflicts of Interest: None.
Authorship: All authors had access to the data and a role in writing this manuscript.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
